复方丹参滴丸联合辛伐他汀治疗冠心病心绞痛疗效观察

Observation on treating angina pectoris from CHD with Fufang Danshen Diwan

【目的】探讨复方丹参滴丸联合辛伐他汀治疗冠心病心绞痛患者临床疗效及对患者血管内皮功能的影响。【方法】选择2013年4月至2014年11月本院收治的105例冠心病心绞痛患者,按照随机分组法分为观察组（n=53）和对照组（n=52）。对照组采用常规对症治疗加用辛伐他汀治疗,观察组在对照组基础上加用复方丹参滴丸治疗,两组均给予4周治疗。对比分析两组疗效、血脂水平、血液流变学水平、血管内皮功能一氧化氮（NO）水平及安全性评价。【结果】观察组心绞痛症状和心电图总有效率均显著高于对照组,且差异均有统计学意义（P〈0.05）。两组总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）水平治疗后较治疗前显著降低（P〈0.05）,且观察组TC、TG、LDL-C水平显著低于对照组,差异均有统计学意义（P〈0.05）。两组全血黏度高切、血小板粘附率、血浆黏度治疗后均较治疗前显著降低（P〈0.05）,且观察组全血黏度高切、血小板粘附率、血浆黏度治疗后显著低于对照组（P〈0.05）。治疗后,两组NO水平较治疗前显著增加（P〈0.05）,且观察组NO水平显著高于对照组（P〈0.05）。【结论】复方丹参滴丸联合辛伐他汀治疗冠心病心绞痛临床疗效显著,可明显改善患者血管内皮功能。

Objective: To investigate the effect of Fufang Danshen Diwan on angina pectoris from coronary heart disease. Methods: 60 patients were randomly divided into the control group and observation group, 30 cases in each. The control group was treated with isosorbide. The observation group was treated with Fufang Danshen Diwan. Results: The total efficiency was 60.0% in the control group, lower than 86.7% in the observation group(P<0.05). The satisfaction rate in the control group was 56.7%, lower than 86.7% in the observation group(P<0.05). There was no significant difference of adverse reactions between two groups(P>0.05). The adverse reaction disappeared with drug-resistance(P>0.05). Conclusion: Fufang Danshen Diwan is effective on angina pectoris from coronary heart disease.